Clinical Trial Update: Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial evaluating natalizumab in combination with standard steroids for high-risk acute graft-versus-host disease; trial completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: John Levine | Conditions: Acute Graft Versus Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-10-21